Detailed Narrative
H1 FY26 Performance and Strategic Adjustments
Aakaar Medical Technologies reported H1 FY26 sales of INR 25.3 crores, an 8.5% year-on-year decline, and a negative PAT of INR 0.78 crores. This performance was attributed to seasonality, one-time📎 costs associated with annual conferences and marketing, and a conscious strategic decision to implement stringent credit controls. The company successfully completed its IPO on the NSE Emerge platform in June 2025, raising INR 27 crores, with most proceeds allocated to strengthening working capital and reducing short-term borrowing.
Focus on Own Brands and Receivables Management
The company is strategically enhancing its own brand portfolio, which now contributes 38% to total turnover, up from 24% previously. Homegrown brands boast higher gross margins of around 70% compared to 60% for imported products. A key focus is to reduce receivable days from a historical 130 days to below 100 days by year-end, aiming for positive cash flow and greater financial stability, despite this being a counter-trend in the aesthetic market.
Product Pipeline and Innovation
Aakaar is expanding its product offerings, with SKUs expected to increase from 154 to over 163-164 this year. New launches include USFDA-approved dermal fillers (Croma-Pharma) and botulinum toxin (Hugel), which are expected to capture significant market share. The company is also entering the regenerative business with a new division called Exovia, launching high-end products from Italy, and has acquired proprietary hair transplant technology.
Market Landscape and Competitive Strategy
Aakaar positions itself as the only aesthetic company in India with the broadest portfolio, covering injectables, skincare, and healthcare solutions for conditions like psoriasis. The company's strategy involves offering better pricing than competitors in India's volume-based market and building a strong doctor-driven sales model. They have added 900 new customers in H1 FY26, contributing to a cumulative base of over 11,000, and train 1,000-2,000 doctors annually.
Regulatory Environment and Compliance
The Indian medical aesthetic market is subject to evolving regulations, with medical devices now requiring mandatory registration under CDSCO's MDR guidelines. Aakaar ensures all its products, including those manufactured locally and imported, are duly licensed and registered with CDSCO, adhering to local BIS standards and FDA approvals. The company's transition from a private limited entity necessitated reapplication for various licenses, impacting inventory levels.
Growth Outlook and Long-term Vision
Despite the H1 challenges, Aakaar maintains a target CAGR of 25-30% and expects a healthy rebound in sales and profitability in H2 FY26. The company aims to reduce its inventory period to 90-120 days and improve EBITDA margins beyond last year's levels. A long-term aspiration is to become the number one player in the Indian aesthetic market, targeting a benchmark of INR 1,000 crores.